TABLE 2.
All patients (n = 154) | MIT (n = 64) | Fumagillin (n = 54) | Nitazoxanide (n = 36) | p | |
---|---|---|---|---|---|
Symptoms | |||||
Diarrhea | 154 (100) | 64 (100) | 54 (100) | 36 (100) | NA |
Fever (>38.5°C) | 8 (5.2) | 5 (7.8) | 1 (1.9) | 2 (5.6) | 0.41 |
Nausea/vomiting | 58 (37.7) | 24 (37.5) | 18 (33.3) | 16 (44.4) | 0.57 |
Asthenia | 32 (20.8) | 15 (23.4) | 10 (18.5) | 7 (19.4) | 0.79 |
Abdominal pain | 31 (20.1) | 16 (25.0) | 5 (9.3) | 10 (27.8) | 0.045 |
Weight loss | 83 (53.9) | 29 (45.3) | 33 (61.1) | 21 (58.3) | 0.19 |
Weight loss (%) (n = 75) | 8 [5; 12] | 7 [5; 13] | 9 [5; 11] | 6 [5; 11] | 0.71 |
Hospitalization rate | 127 (82.5) | 47 (73.4) | 50 (92.6) | 30 (83.3) | 0.02 |
Serum creatinine (µmol/L) (n = 150) | 187 [124; 293] (43; 838) | 182 [136; 285] (85; 653) | 191 [129; 278] (43; 838) | 216 [118; 311] (85; 676) | 0.88 |
Renal failure | 55/100 (55.0) | 27/49 (55.1) | 14/23 (60.9) | 14/28 (50.0) | 0.74 |
AKIN stage | 0.22 | ||||
1 | 21/55 (38.2) | 14/27 (51.9) | 3/14 (21.4) | 4/14 (28.6) | |
2 | 14/55 (25.4) | 7/27 (25.9) | 4/14 (28.6) | 3/14 (21.4) | |
3 | 20/55 (36.4) | 6/27 (22.2) | 7/14 (50.0) | 7/14 (50.0) | |
CRP (mg/L) (n = 115) | 4 [1; 11] | 3 [1; 11] | 5 [2; 15] | 3 [1; 8] | 0.31 |
Hemoglobin (g/dL) (n = 150) | 11.6 [10.1; 12.9] | 11.4 [10.0; 12.4] | 11.7 [10.3; 13.4] | 11.9 [10.1; 12.9] | 0.87 |
Platelets (G/L) (n = 133) | 226 [169; 268] | 236 [168; 279] | 219 [165; 264] | 217 [173; 263] | 0.96 |
PNN (G/L) (n = 133) | 4.7 [3.3; 6.6] | 4.7 [3.1; 7.1] | 5.3 [3.3; 8.1] | 4.5 [3.3; 5.8] | 0.33 |
Lymphocyte (G/L) (n = 130) | 1.08 [0.64; 1.60] | 1.19 [0.77; 1.82] | 1.10 [0.64; 1.81] | 1.01 [0.51; 1.30] | 0.08 |
Data are presented as number of patients (percentages), or median [25th; 75th percentiles] (range). Comparisons between groups were made with Chi-squared test or Fisher’s exact test for categorical data, and with Kruskal-Wallis test for quantitative data. In the first column, “n” is the number of available data when there is missing data. AKIN: acute kidney injury network (score 3 is more serious than score 1); CRP: C-reactive protein; MIT: modification of immunosuppressive treatment; NA: not applicable; PNN: polynuclear neutrophil.